Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when VNRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsVolitionRx executes 1-for-20 reverse stock split, reducing share count by 95%
Filed April 28, 2026 · Period ending April 28, 2026 · ~1 min read
Key Changes
-
high
Reverse stock split became effective April 28, 2026, consolidating every 20 shares into 1 share. This aggressive ratio typically aims to boost per-share price and maintain exchange listing compliance.
Item 5.03 verify on EDGAR → -
high
Board selected the 1-for-20 ratio from a range previously authorized by stockholders at March 31, 2026 special meeting. Shareholders' ownership percentages remain unchanged despite reduced share count.
Item 5.03 verify on EDGAR → -
medium
Company filed Certificate of Amendment with Delaware on April 27, 2026, formalizing the split and establishing treatment for fractional shares resulting from the consolidation.
Item 5.03 verify on EDGAR →
Summary
VolitionRx implemented a 1-for-20 reverse stock split effective April 28, 2026, one of the more aggressive consolidation ratios companies employ. The move reduces the outstanding share count by 95% while proportionally increasing the per-share price. This action follows stockholder approval at a March 31 special meeting and was formalized through a certificate amendment filed with Delaware authorities.
Retail investors should understand that while their ownership percentage stays the same, reverse splits often signal distress—companies typically use them to avoid delisting when share prices fall below exchange minimums. The 1-for-20 ratio suggests VolitionRx's stock had declined significantly.
Watch the post-split trading price closely: if shares quickly drift back toward $1-2 range, the company may face renewed compliance issues. Also monitor whether management provides updated guidance on business fundamentals, as reverse splits address symptoms rather than underlying performance challenges.
Section-by-Section Diff
Event · Item 5.03 — Amendments to Articles of Incorporation or Bylaws
Item 5.03 — Amendments to Articles of Incorporation or Bylaws filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On April 27, 2026, the Company filed a Certificate of Third Amendment of the Second Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Delaware Secretary of State, which amended Section 6.1 of Article 6 of the Restated Certificate, effective as of 12:01 a.m. ET on April 28, 2026, to (i) give effect to the Reverse Stock Split, and (ii) describe the treatment of any fractional shares of Common Stock upon the effectiveness of the Reverse Stock Split.
The company formally executed a reverse stock split by filing an amendment to its certificate of incorporation with Delaware, effective April 28, 2026. This consolidates every 20 shares of common stock into 1 share, reducing the total share count proportionally while maintaining each shareholder's ownership percentage. The amendment also addresses how fractional shares resulting from the split will be handled.
Added in current filing · verify on EDGAR →
The Board subsequently approved the Reverse Stock Split at a ratio of one-for-twenty.
The board of directors selected a 1-for-20 ratio from the range previously authorized by stockholders at the March 31, 2026 special meeting. This is a relatively aggressive consolidation ratio that will reduce the outstanding share count by 95%, typically done to boost per-share price and maintain exchange listing requirements.
Event · Item 9.01 — Financial Statements and Exhibits
VolitionRx filed a third amendment to its certificate of incorporation; specific changes not disclosed in 8-K body.
Added in current filing · verify on EDGAR →
Certificate of Third Amendment of the Second Amended and Restated Certificate of Incorporation of VolitionRx Limited
The company filed a third amendment to its certificate of incorporation. The 8-K body does not disclose the substance of the amendment; investors must review Exhibit 3.1 to understand what corporate governance or capital structure changes were made.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jun 2, 2026 · How we verify